Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleClinical Studies

Phase II Trial of Carboplatin, Paclitaxel Plus Vinorelbine in Non-small Cell Lung Cancer Patients

ALEXANDER SCHMITTEL, JAN MICHAEL SIEHL, MANFRED SCHULZE, KARSTEN SCHULZE, ECKHARD THIEL and ULRICH KEILHOLZ
Anticancer Research March 2005, 25 (2B) 1333-1336;
ALEXANDER SCHMITTEL
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: alexander.schmittel@charite.de
JAN MICHAEL SIEHL
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MANFRED SCHULZE
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KARSTEN SCHULZE
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ECKHARD THIEL
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ULRICH KEILHOLZ
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading

Article Information

vol. 25 no. 2B 1333-1336
PubMed 
15865087

Published By 
International Institute of Anticancer Research
Print ISSN 
0250-7005
Online ISSN 
1791-7530
History 
  • Received August 23, 2004
  • Revision received January 3, 2005
  • Accepted February 7, 2005
  • Published online March 1, 2005.

Copyright & Usage 
Copyright© 2005 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved

Author Information

  1. ALEXANDER SCHMITTEL1,
  2. JAN MICHAEL SIEHL1,
  3. MANFRED SCHULZE3,
  4. KARSTEN SCHULZE2,
  5. ECKHARD THIEL1 and
  6. ULRICH KEILHOLZ1
  1. 1Department of Medicine III (Hematology, Oncology and Transfusionmedicine), University Medicine of Berlin, Charité, Campus Benjamin Franklin, Hindenburgdamm 30, 12200 Berlin
  2. 2Department of Medicine II (Cardiology and Pulmology), University Medicine of Berlin, Charité, Campus Benjamin Franklin, Hindenburgdamm 30, 12200 Berlin
  3. 3Kreiskrankenhaus Zittau, Department of Hematology and Oncology, Goerlitzerstr. 10, 02763 Zittau, Germany
  1. Correspondence to: Alexander Schmittel, M.D., Charité, Campus Benjamin Franklin, Department of Medicine III, (Hematology, Oncology and Transfusion Medicine), Hindenburgdamm 30, D-12200 Berlin, Germany. Tel: 49-30-8445-3906, Fax: 49-30-8445-4468, e-mail: alexander.schmittel{at}charite.de

Cited By...

  • 3 Citations
  • Google Scholar
PreviousNext
Back to top

In this issue

Anticancer Research: 25 (2B)
Anticancer Research
Vol. 25, Issue 2B
1 Mar 2005
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Phase II Trial of Carboplatin, Paclitaxel Plus Vinorelbine in Non-small Cell Lung Cancer Patients
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
1 + 6 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Phase II Trial of Carboplatin, Paclitaxel Plus Vinorelbine in Non-small Cell Lung Cancer Patients
ALEXANDER SCHMITTEL, JAN MICHAEL SIEHL, MANFRED SCHULZE, KARSTEN SCHULZE, ECKHARD THIEL, ULRICH KEILHOLZ
Anticancer Research Mar 2005, 25 (2B) 1333-1336;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Phase II Trial of Carboplatin, Paclitaxel Plus Vinorelbine in Non-small Cell Lung Cancer Patients
ALEXANDER SCHMITTEL, JAN MICHAEL SIEHL, MANFRED SCHULZE, KARSTEN SCHULZE, ECKHARD THIEL, ULRICH KEILHOLZ
Anticancer Research Mar 2005, 25 (2B) 1333-1336;
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Efficacy and Safety of Lenvatinib After Progression on First-line Atezolizumab Plus Bevacizumab Treatment in Advanced Hepatocellular Carcinoma Patients
  • Efficacy and Safety of Platinum-based Chemotherapy With Bevacizumab Followed by Bevacizumab Maintenance for Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer During PARP Inhibitor Therapy: A Multicenter Retrospective Study
  • Real-world Data of Palliative First-line Checkpoint Inhibitor Therapy for Head and Neck Cancer
Show more Clinical Studies

Similar Articles

Anticancer Research

© 2023 Anticancer Research

Powered by HighWire